A composition contains at least one fucosylated oligosaccharide, for use in preventing and/or treating a URT infection in an infant or young child fulfilling at least one of the following criteria: i) the infant or young child is born from a non-secretor mother and/or is fed with a mother's milk deficient in at least one fucosylated oligosaccharide, ii) the infant or young child has at least one sibling, and iii) the infant or young child was born by C-section.

A composition contains at least one fucosylated oligosaccharide, for use in preventing and/or treating a URT infection in an infant or young child fulfilling at least one of the following criteria: i) the infant or young child is born from a non-secretor mother and/or is fed with a mother's milk deficient in at least one fucosylated oligosaccharide, ii) the infant or young child has at least one sibling, and iii) the infant or young child was born by C-section.

The application of the addition and subtraction of Er Chen Tang in the preparation of medicine or health care products for the treatment of pulmonary fungal diseases belongs to the medical and health care field, which specifically relates to the use of alkaloids and volatile oils contained in Pinellia ternate, Tangerine peel, Liquorice, Coix seed, Gastrodia elata in the preparation of medicine or health care products for the treatment of pulmonary fungal diseases.

The application of the addition and subtraction of Er Chen Tang in the preparation of medicine or health care products for the treatment of pulmonary fungal diseases belongs to the medical and health care field, which specifically relates to the use of alkaloids and volatile oils contained in Pinellia ternate, Tangerine peel, Liquorice, Coix seed, Gastrodia elata in the preparation of medicine or health care products for the treatment of pulmonary fungal diseases.

The present disclosure relates to a method of altering intestinal microbiome in a patient having cystic fibrosis comprising administering at least one of Bifidobacterium and/or Bacteroides to a patient and allowing the Bifidobacterium and/or Bacteroides to alter the intestinal microbiome.

The present disclosure relates to a method of altering intestinal microbiome in a patient having cystic fibrosis comprising administering at least one of Bifidobacterium and/or Bacteroides to a patient and allowing the Bifidobacterium and/or Bacteroides to alter the intestinal microbiome.

A method for or treating respiratory disease according to an embodiment includes administering to a subject in need thereof an extract of Siraitia grosvenorii residuals as an effective component. The extract of Siraitia grosvenorii residuals has, in an animal model having asthma induced by ovalbumin (OVA), an effect of reducing airway hyper-responsiveness, inhibiting inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing Th2 cytokines (IL-4, IL-5, and IL-13) in BALF, reducing inflammation and tissue damage in lung tissues, inhibiting contraction of airway smooth muscle and airway inflammation, an effect of inhibiting expression of IL-13, TARC, TNF-α, IL-17, and MUC5AC, which is a gene encoding mucus protein, in lung tissues, an effect of reducing the level of ovalbumin-specific IgE in blood serum, and an effect of reducing ROS in alveolar cells which is generated in excess amount due to fine dust.

A method for or treating respiratory disease according to an embodiment includes administering to a subject in need thereof an extract of Siraitia grosvenorii residuals as an effective component. The extract of Siraitia grosvenorii residuals has, in an animal model having asthma induced by ovalbumin (OVA), an effect of reducing airway hyper-responsiveness, inhibiting inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing Th2 cytokines (IL-4, IL-5, and IL-13) in BALF, reducing inflammation and tissue damage in lung tissues, inhibiting contraction of airway smooth muscle and airway inflammation, an effect of inhibiting expression of IL-13, TARC, TNF-α, IL-17, and MUC5AC, which is a gene encoding mucus protein, in lung tissues, an effect of reducing the level of ovalbumin-specific IgE in blood serum, and an effect of reducing ROS in alveolar cells which is generated in excess amount due to fine dust.

The present invention relates to a pharmaceutical composition for preventing or treating respiratory disease, which comprises an alcohol or organic solvent extract of Justicia procumbens L. as an active ingredient, and to a pharmaceutical composition for preventing or treating respiratory disease, which comprises an alcohol or organic solvent extract of Justicia procumbens L., the extract comprising any one or more of justicidin A, justicidin B, justicidin C and phyllamyricin C, and also to a food composition for preventing or treating respiratory disease, which comprises the alcohol or organic solvent extract. The composition comprising the Justicia procumbens L. extract according to the present invention may inhibit abnormal overproliferation of splenocytes, may inhibit the secretion of allergic inflammatory cytokines, and exhibits an expectorant effect and an airway constriction inhibitory effect. Thus, it may effectively prevent, treat or improve respiratory disease.

The present application discloses a nutritional composition for moisturizing lung. The nutritional composition includes the following components of raw materials in parts by weight: rice 55-90, wheat 7-25, Chinese yam 3-15, lily 2-9, polygonatum odoratum 0.2-1, and citron 0.1-1. The present disclosure, in view of the lung's characteristics of being not resistant to cold or heat, and susceptible to pathogen, complies with the lung's physiological function characteristics to regulate, and provides the prescription with nourishing yin and moisturizing lung, and resolving phlegm and relieving cough as a starting point, is suitable to cooperate with staple foods for long-term consumption and easily accepted by people due to the good taste, and can achieve certain efficacies of replenishing and restoring lung qi.